Methods for the detection of tumor-specific single nucleotide somatic mutations in plasma cDNA samples

Introduction. Liquid biopsy is considered as a minimally invasive method of molecular genetic analysis that can be used for early diagnosis, prognosis of disease development, monitoring of residual disease or treatment outcomes, and selection of optimal drug therapy schemes for a patient. Along with...

Full description

Bibliographic Details
Main Authors: L. M. Dyakov, O. M. Krivtsova, P. A. Khesina, I. F. Kustova, N. A. Dyakova, N. S. Muge, N. E. Kudashkin, Yu. I. Patyutko, N. L. Lazarevich
Format: Article
Language:Russian
Published: ABV-press 2022-10-01
Series:Успехи молекулярной онкологии
Subjects:
Online Access:https://umo.abvpress.ru/jour/article/view/457
_version_ 1797700186589364224
author L. M. Dyakov
O. M. Krivtsova
P. A. Khesina
I. F. Kustova
N. A. Dyakova
N. S. Muge
N. E. Kudashkin
Yu. I. Patyutko
N. L. Lazarevich
author_facet L. M. Dyakov
O. M. Krivtsova
P. A. Khesina
I. F. Kustova
N. A. Dyakova
N. S. Muge
N. E. Kudashkin
Yu. I. Patyutko
N. L. Lazarevich
author_sort L. M. Dyakov
collection DOAJ
description Introduction. Liquid biopsy is considered as a minimally invasive method of molecular genetic analysis that can be used for early diagnosis, prognosis of disease development, monitoring of residual disease or treatment outcomes, and selection of optimal drug therapy schemes for a patient. Along with the development of tests based on the study of panels of oncologically significant genes or their regions, for various forms of genetically heterogeneous tumors a promising approach could be the use as an object of liquid biopsy of an individual spectrum of somatic mutations of a particular patient that can be detected on the basis of high-throughput sequencing of tumor tissue.Aim. To determine the applicability of different methods for detecting single-nucleotide somatic mutations detected in tumor tissue of a particular patient in cDNA preparations from blood plasma obtained before surgical removal of the tumor and to evaluate the possibility of quantifying the proportion of the alternative variant in the total pool of cDNA. Materials and methods. We used normal and tumor tissue, as well as blood plasma samples from patients with hepatocellular carcinoma, and various methods for detecting single-nucleotide somatic mutations: real-time polymerase chain reaction (PCR) with intercalating dye or with TaqMan probes, droplet digital PCR and high-throughput sequencing of target amplicons.Results. Using the example of a somatic mutation in the TLN1 gene detected in tumor tissue of a patient with hepatocellular carcinoma, methods were developed and tested, each of which allows specific detection of the mutant variant in small amounts (2 ng) of cDNA from the blood plasma of the same patient. The use of droplet PCR and target amplicon sequencing methods allowed us to quantify the proportion of the mutant variant in the total cDNA pool, which was 19.7 and 23.5 %, respectively.Conclusion. Among the methods investigated, droplet digital PCR and targeted amplicon sequencing allow not only reliable detection of mutant variants in small amounts of cDNA, but also adequate quantification, which is particularly important for the development of ways to monitor tumor growth during treatment. The close values of the proportion of mutant variants in cDNA detected by these methods indicate the accuracy of quantitative analysis and the possibility of their use for cross-validation of the results obtained.
first_indexed 2024-03-12T04:18:19Z
format Article
id doaj.art-bb5ea6205d614e978845c573da264991
institution Directory Open Access Journal
issn 2313-805X
2413-3787
language Russian
last_indexed 2024-03-12T04:18:19Z
publishDate 2022-10-01
publisher ABV-press
record_format Article
series Успехи молекулярной онкологии
spelling doaj.art-bb5ea6205d614e978845c573da2649912023-09-03T10:34:42ZrusABV-pressУспехи молекулярной онкологии2313-805X2413-37872022-10-0193243710.17650/2313-805X-2022-9-3-24-37250Methods for the detection of tumor-specific single nucleotide somatic mutations in plasma cDNA samplesL. M. Dyakov0O. M. Krivtsova1P. A. Khesina2I. F. Kustova3N. A. Dyakova4N. S. Muge5N. E. Kudashkin6Yu. I. Patyutko7N. L. Lazarevich8ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава РоссииФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава РоссииФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава России; ФГБОУ ВО «Московский государственный университет им. М. В. Ломоносова»ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава РоссииФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава РоссииФГБНУ «Всероссийский научно-исследовательский институт рыбного хозяйства и океанографии»; ФГБУН «Институт биологии развития им. Н. К. Кольцова Российской академии наук»ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава РоссииФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава РоссииФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава России; ФГБОУ ВО «Московский государственный университет им. М. В. Ломоносова»Introduction. Liquid biopsy is considered as a minimally invasive method of molecular genetic analysis that can be used for early diagnosis, prognosis of disease development, monitoring of residual disease or treatment outcomes, and selection of optimal drug therapy schemes for a patient. Along with the development of tests based on the study of panels of oncologically significant genes or their regions, for various forms of genetically heterogeneous tumors a promising approach could be the use as an object of liquid biopsy of an individual spectrum of somatic mutations of a particular patient that can be detected on the basis of high-throughput sequencing of tumor tissue.Aim. To determine the applicability of different methods for detecting single-nucleotide somatic mutations detected in tumor tissue of a particular patient in cDNA preparations from blood plasma obtained before surgical removal of the tumor and to evaluate the possibility of quantifying the proportion of the alternative variant in the total pool of cDNA. Materials and methods. We used normal and tumor tissue, as well as blood plasma samples from patients with hepatocellular carcinoma, and various methods for detecting single-nucleotide somatic mutations: real-time polymerase chain reaction (PCR) with intercalating dye or with TaqMan probes, droplet digital PCR and high-throughput sequencing of target amplicons.Results. Using the example of a somatic mutation in the TLN1 gene detected in tumor tissue of a patient with hepatocellular carcinoma, methods were developed and tested, each of which allows specific detection of the mutant variant in small amounts (2 ng) of cDNA from the blood plasma of the same patient. The use of droplet PCR and target amplicon sequencing methods allowed us to quantify the proportion of the mutant variant in the total cDNA pool, which was 19.7 and 23.5 %, respectively.Conclusion. Among the methods investigated, droplet digital PCR and targeted amplicon sequencing allow not only reliable detection of mutant variants in small amounts of cDNA, but also adequate quantification, which is particularly important for the development of ways to monitor tumor growth during treatment. The close values of the proportion of mutant variants in cDNA detected by these methods indicate the accuracy of quantitative analysis and the possibility of their use for cross-validation of the results obtained.https://umo.abvpress.ru/jour/article/view/457гепатоцеллюлярная карциномациркулирующая днксоматические мутациижидкостная биопсия
spellingShingle L. M. Dyakov
O. M. Krivtsova
P. A. Khesina
I. F. Kustova
N. A. Dyakova
N. S. Muge
N. E. Kudashkin
Yu. I. Patyutko
N. L. Lazarevich
Methods for the detection of tumor-specific single nucleotide somatic mutations in plasma cDNA samples
Успехи молекулярной онкологии
гепатоцеллюлярная карцинома
циркулирующая днк
соматические мутации
жидкостная биопсия
title Methods for the detection of tumor-specific single nucleotide somatic mutations in plasma cDNA samples
title_full Methods for the detection of tumor-specific single nucleotide somatic mutations in plasma cDNA samples
title_fullStr Methods for the detection of tumor-specific single nucleotide somatic mutations in plasma cDNA samples
title_full_unstemmed Methods for the detection of tumor-specific single nucleotide somatic mutations in plasma cDNA samples
title_short Methods for the detection of tumor-specific single nucleotide somatic mutations in plasma cDNA samples
title_sort methods for the detection of tumor specific single nucleotide somatic mutations in plasma cdna samples
topic гепатоцеллюлярная карцинома
циркулирующая днк
соматические мутации
жидкостная биопсия
url https://umo.abvpress.ru/jour/article/view/457
work_keys_str_mv AT lmdyakov methodsforthedetectionoftumorspecificsinglenucleotidesomaticmutationsinplasmacdnasamples
AT omkrivtsova methodsforthedetectionoftumorspecificsinglenucleotidesomaticmutationsinplasmacdnasamples
AT pakhesina methodsforthedetectionoftumorspecificsinglenucleotidesomaticmutationsinplasmacdnasamples
AT ifkustova methodsforthedetectionoftumorspecificsinglenucleotidesomaticmutationsinplasmacdnasamples
AT nadyakova methodsforthedetectionoftumorspecificsinglenucleotidesomaticmutationsinplasmacdnasamples
AT nsmuge methodsforthedetectionoftumorspecificsinglenucleotidesomaticmutationsinplasmacdnasamples
AT nekudashkin methodsforthedetectionoftumorspecificsinglenucleotidesomaticmutationsinplasmacdnasamples
AT yuipatyutko methodsforthedetectionoftumorspecificsinglenucleotidesomaticmutationsinplasmacdnasamples
AT nllazarevich methodsforthedetectionoftumorspecificsinglenucleotidesomaticmutationsinplasmacdnasamples